Aptevo Therapeutics Inc APVO:NASDAQ

Last Price$7.03NASDAQ Previous Close - Last Trade as of 4:00PM ET 12/03/21
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$7.05 (10)
Ask (Size)$7.18 (12)
Day Low / HighN/A - N/A
Volume659.6 K

View Biotechnology IndustryPeer Comparison as of 12/03/2021


Aptevo Therapeutics Inc ( NASDAQ )

Price: $7.03
Change: -1.01 (12.56%)
Volume: 659.6 K
4:00PM ET 12/03/2021

Soligenix Inc ( NASDAQ )

Price: $0.80
Change: +0.02 (2.54%)
Volume: 401.0 K
4:00PM ET 12/03/2021

Pulmatrix Inc ( NASDAQ )

Price: $0.62
Change: -0.01 (1.53%)
Volume: 463.2 K
4:00PM ET 12/03/2021

Catalyst Biosciences Inc ( NASDAQ )

Price: $1.09
Change: -0.04 (3.54%)
Volume: 662.3 K
4:00PM ET 12/03/2021

Navidea Biopharmaceuticals Inc ( NYSE MKT LLC )

Price: $1.15
Change: -0.07 (5.74%)
Volume: 46.7 K
8:00PM ET 12/03/2021

Read more news Recent News

Top Premarket Decliners
8:21AM ET 11/24/2021 MT Newswires

Kura Oncology (KURA) shares slumped 28% after the US Food and Drug Administration placed the company's KO-539 study on partial hold following a patient...

Top Midday Gainers
1:41PM ET 11/23/2021 MT Newswires

Aptevo Therapeutics (APVO) said a high-risk acute myeloid leukemia patient treated with a combination of chemotherapy plus its APVO436 "achieved a complete...

Aptevo Reports First Complete Remission in Trial of Acute Myeloid Leukemia Cell Therapy; Shares Surge
1:26PM ET 11/23/2021 MT Newswires

Aptevo Therapeutics (APVO) said Tuesday a high-risk acute myeloid leukemia patient treated with a combination of chemotherapy and its APVO436 experimental...

Insider Sell: Aptevo Therapeutics
5:32PM ET 11/22/2021 MT Newswires

Kevin C Tang, 10% Owner, on November 18, 2021, sold 838,664 shares in Aptevo Therapeutics (APVO) for $6,500,411. Following the Form 4 filing with the SEC,...

View all Commentary and Analysis

An Assessment On Aptevo Therapeutics
7:05AM ET 3/24/2021 Seeking Alpha

Company Profile

Business DescriptionAptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527 and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded on February 22, 2016 and is headquartered in Seattle, WA. View company web site for more details
Address2401 4th Avenue
Seattle, Washington 98121
Number of Employees118
Recent SEC Filing11/26/2021SC 13D/A
President, Chief Executive Officer & DirectorMarvin L. White
Chief Financial Officer, Treasurer & Senior VPJeffrey G. Lamothe
Chief Medical Officer & SVP-Clinical DevelopmentScott C. Stromatt
SVP, General Counsel & Head-Corporate AffairsSoYoung Kwon

Company Highlights

Price Open$8.01
Previous Close$8.04
52 Week Range$6.38 - 46.66
Market Capitalization$34.4 M
Shares Outstanding4.9 M
SectorHealth Technology
Next Earnings Announcement02/11/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$6.54
Beta vs. S&P 500N/A
Revenue$23.1 M
Net Profit Margin-272.56%
Return on Equity-248.45%

Analyst Ratings as of 08/30/2021

Consensus RecommendationConsensus Icon
Powered by Factset